Inscripta
Ingredient supplier
- Public category
- Ingredient supplier
- Ingredients
- 1
- Declared capabilities
- 6
- Headquarters
- United States
Overview
What Inscripta covers.
Inscripta was a genome editing technology company that developed programmable CRISPR-based tools for precision genome engineering. Their products included the MAD7® nuclease — a freely licensable CRISPR enzyme — and the Onyx® Genome Engineering Platform for large-scale multiplex gene editing in microbial and mammalian cells. In 2023, Inscripta merged with Manus Bio to create a combined platform for developing bio-based alternative ingredients.
- Inscripta supplies ingredients including MAD7 Nuclease.
- Declared capabilities: CRISPR genome editing, Multiplex gene editing, High-throughput genome engineering and CRISPR nuclease development and licensing.
- Headquartered in United States.
- Talio tracks 7,650 food and beverage companies headquartered or distributing in United States. Browse Companies in United States
- Talio tracks 572 ingredient suppliers headquartered or distributing in United States. Browse Ingredient suppliers in United States
Capabilities & ingredients
Capabilities
Ingredients
FAQ
Questions this page answers.
What does Inscripta do?
Inscripta is a ingredient supplier based in United States with declared capabilities in CRISPR genome editing, Multiplex gene editing and High-throughput genome engineering, tracked in Talio's food and beverage intelligence platform.
Which ingredients does Inscripta supply?
Inscripta supplies MAD7 Nuclease.
Is this the full Talio record?
No. This page is a public preview; proprietary metrics and workflow features remain inside authenticated Talio.
Proprietary metrics remain in authenticated Talio.